SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Innovation Pharmaceuticals Inc. (IPIX)

IPIX RSS Feed
Add IPIX Price Alert      Hide Sticky   Hide Intro
Moderator: LilBigKahuna, BooDog, sox040713, Astavakra, Matagordaville, scottsmith
Search This Board: 
Last Post: 9/21/2017 5:59:46 AM - Followers: 716 - Board type: Free - Posts Today: 2

Innovation Pharmaceuticals Inc. (IPIX)

https://www.sec.gov/Archives/edgar/data/1355250/000147793217002710/ctix_8k.htm
 

http://www.ipharminc.com/

 
Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
Phone: 978-236-8717
Fax:  978-921-6564
Email:  info@ipharminc.com

 
About Innovation Pharmaceuticals Inc.: 

Headquartered in Beverly, Massachusetts, Innovation Pharmaceuticals is a publicly-traded company under the symbol "IPIX".
Innovation Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative therapies in multiple diseases. Innovation Pharmaceuticals believes it has a world-class portfolio of first-in-class lead drug candidates and is now advancing them toward market approval, while actively seeking strategic partnerships. Innovation Pharmaceuticals' psoriasis drug candidate Prurisol completed a Phase 2 trial and Innovation Pharmaceuticals is nearing completion of a Phase 2b study. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Innovation Pharmaceuticals' anti-cancer drug Kevetrin successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center, and Innovation Pharmaceuticals has commenced a Phase 2 study. In the laboratory, Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Innovation Pharmaceuticals is in a Phase 2 clinical trial with its novel compound Brilacidin-OM (a defensin mimetic compound) for the prevention of oral mucositis in patients with head and neck cancer. Interim analysis has shown Brilacidin-OM to have a high potential for prevention of severe oral mucositis. Clinical results are consistent with those seen in an animal model in which the occurrence of severe ulcerative oral mucositis was reduced by more than 94% compared to placebo. Innovation Pharmaceuticals' lead antibiotic, Brilacidin, has completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the FDA-approved seven-day dosing regimen of daptomycin. Brilacidin has the potential to be a single-dose therapy for certain multi-drug resistant bacteria ("superbugs"). In an ongoing Phase 2 open label Proof-of-Concept trial, favorable interim results have been observed in the first two cohorts of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).  Innovation Pharmaceuticals has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available at http://www.ipharminc.com.

Management: http://www.cellceutix.com/senior-management/

Ongoing Human Trials:  http://clinicaltrials.gov/ct2/results?term=Cellceutix+Pharmaceuticals&Search=Search
 
Product Pipeline:  http://www.ipharminc.com/therapeutic-areas/

 

PIPELINE: 

FDA DESIGNATIONS:

MILESTONES:


Recent News and Press Releases: 
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/

 
SEC Filings (CIK:0001355250): 
https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany

Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com

 
Share Structure:  See SEC filing link above for current share structure

 

Cellceutix IP - Patent Filings:

EPO
http://worldwide.espacenet.com/searchResults?PA=Cellceutix&DB=EPODOC&locale=en_EP&ST=advanced&compact=false
WIPO
http://www.wipo.int/patentscope/search/en/detail.jsf?docId=WO2010135170&recNum=1&docAn=US2010034838&queryString=FP:(Cellceutix)&maxRec=1
USPTO
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=0&f=S&l=50&TERM1=Cellceutix&FIELD1=AS&co1=AND&TERM2=&FIELD2=&d=PG01 


http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8,796,275.PN.&OS=PN/8,796,275&RS=PN/8,796,275
 

Publication number US8338454 B2
Publication type Grant
Application number US 12/780,132
Publication date Dec 25, 2012
Filing date May 14, 2010
Priority date May 20, 2009
Also published as CA2762427A1, CN102438612A, EP2432464A2, US20100298374, US20130245062, WO2010135170A2, WO2010135170A3, Less «6 More »
Publication number 12780132, 780132, US 8338454 B2, US 8338454B2, US-B2-8338454, US8338454 B2, US8338454B2
Inventors Krishna Menon
Original Assignee Cellceutix Corporation
Export Citation BiBTeX, EndNote, RefMan
Patent Citations (6), Non-Patent Citations (41), Referenced by (1), Classifications (42)
 
External Links: USPTO, USPTO Assignment, Espacenet

http://www.google.com/patents/US8338454

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=6&f=G&l=50&co1=AND&d=PG01&s1=Cellceutix.AS.&OS=AN/Cellceutix&RS=AN/Cellceutix

 
Investor Relations: 

http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1


Following is a DAILY chart:


 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
 
Also, keep in mind that moderators may or may not have a position in said stock.  Being a moderator isn’t a sign of endorsement.
 
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
IPIX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IPIX News: Securities Registration Statement (simplified Form) (s-3) 09/11/2017 12:47:10 PM
IPIX News: Annual Report (10-k) 09/11/2017 06:04:38 AM
IPIX News: Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) 09/11/2017 06:04:37 AM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:27:18 PM
IPIX News: Statement of Changes in Beneficial Ownership (4) 09/06/2017 06:24:45 PM
PostSubject
#197146  Sticky Note 4th Quarter catalysts approaching BooDog 09/16/17 07:09:34 AM
#196902  Sticky Note IPIX Milestones, Clinical Trials, Recent Interviews, Corporate Overview, Patents sox040713 09/14/17 06:23:42 PM
#196731  Sticky Note I sent this artilce to Leo,.... looks like cabel 09/14/17 08:36:29 AM
#196630  Sticky Note Proof of Concept (PoC) studies -- the exact slcimmuno 09/13/17 12:06:33 PM
#191428  Sticky Note $IPIX - Innovation Pharmaceuticals Stock May Be A LilBigKahuna 07/23/17 12:25:32 AM
#187085  Sticky Note When it is easier to find an off IH Admin [Edward] 06/23/17 04:39:38 PM
#197716   I'm hoping all longs (even those who normally cybermich 09/21/17 05:59:46 AM
#197715   Nerby, I used that image to refute the sox040713 09/21/17 01:31:11 AM
#197714   Kevetrin, the number 1 reason. Why most DaubersUP 09/20/17 11:24:52 PM
#197713   On that point you're right: if the data nerby 09/20/17 11:08:46 PM
#197712   Nope, nor is it green check-marked as "delivered". nerby 09/20/17 10:53:31 PM
#197711   Thanks. Looking on my phone and didn't scottsmith 09/20/17 10:23:46 PM
#197710   It's a change. Welcome to pre-revenue biotech. Is Jhawker 09/20/17 10:18:27 PM
#197709   No... it's not checked. And, it's also KarinCA 09/20/17 09:57:00 PM
#197708   Despicable is the correct word. TheDane 09/20/17 09:51:25 PM
#197707   Wait -- is interim analysis for phase 2b scottsmith 09/20/17 09:45:04 PM
#197706   Sox, I'm sure you've taken a gander at nerby 09/20/17 09:19:54 PM
#197705   I'm just catching up. Read this about Kevetrin nerby 09/20/17 09:15:50 PM
#197704   Jhawk unless they partner /sell out the JTORENCE 09/20/17 08:16:49 PM
#197703   scottsmith and it won't be available for at JTORENCE 09/20/17 08:11:54 PM
#197702   nerby obvious they have swept it under the JTORENCE 09/20/17 08:05:52 PM
#197700   100 million market cap could be fairly priced septmike09 09/20/17 08:00:56 PM
#197699   New investors are needed to see a rise KarinCA 09/20/17 07:42:28 PM
#197698   I do agree that the hit pieces played scottsmith 09/20/17 07:30:39 PM
#197697   I blame mgmt and the CEO. bloated MXAMDUD 09/20/17 07:27:09 PM
#197696   Mako's first attack along with Rosen's lawsuit dropped sox040713 09/20/17 07:25:26 PM
#197695   Karin. Here here! groton68 09/20/17 07:22:38 PM
#197694   I don't blame retail or regular shareholders. KarinCA 09/20/17 07:18:21 PM
#197693   Why blame Mako - he is there to Amatuer17 09/20/17 07:12:12 PM
#197691   It is ignorant to keep repeating the same groton68 09/20/17 07:10:23 PM
#197688   No your wrong. They have done a great Jhawker 09/20/17 07:07:49 PM
#197687   You can thank Mako, someone you have never sox040713 09/20/17 07:07:14 PM
#197686   You cannot blame people - this is just Amatuer17 09/20/17 07:06:09 PM
#197684   I agree Karen the tactic of short and Jhawker 09/20/17 07:02:28 PM
#197683   I never said ipix should have K approved. scottsmith 09/20/17 07:01:55 PM
#197681   It is just in books - my point Amatuer17 09/20/17 07:01:42 PM
#197680   Fully agree and that is why I'm always KarinCA 09/20/17 06:55:31 PM
#197679   I disagree. Phase 1 took a long time sox040713 09/20/17 06:54:48 PM
#197676   Leo has delivered five events this year. Two sox040713 09/20/17 06:37:50 PM
#197675   When or if IPIX executes it near term tryz 09/20/17 06:28:45 PM
#197674   I agree. I also believe ipix managerial scottsmith 09/20/17 06:25:04 PM
#197673   The most recent short interest is < 1% sox040713 09/20/17 06:22:56 PM
#197672   Sorry to hear about your friend and I thefamilyman 09/20/17 06:21:32 PM
#197671   FINRA short sales of IPIX AlanC 09/20/17 06:20:16 PM
#197669   B the antibiotic is everywhere. sox040713 09/20/17 06:08:28 PM
#197668   False, it was never there before untohim 09/20/17 06:02:11 PM
#197667   Seems like the blurb targeting P53 is new....did untohim 09/20/17 05:57:13 PM
#197666   Please explain the rationale of investing in this sox040713 09/20/17 05:55:04 PM
#197665   Wish leo would update us on why the snayeman 09/20/17 05:51:04 PM
#197664   So 7 trading days left in Q3. Anyone krobar 09/20/17 05:49:01 PM
#197662   Worldwide Oral Mucositis Market Will Grow Steady at sox040713 09/20/17 05:42:10 PM
#197661   you have said this over and over and untohim 09/20/17 05:38:34 PM
#197660   Don't hold your breath on this one. We jav0033 09/20/17 05:23:16 PM
#197659   Yup. Only change I've noted is that the nerby 09/20/17 05:10:01 PM
#197658   back online. DoubleJ23 09/20/17 05:00:41 PM
#197656   Looks that way to me. DoubleJ23 09/20/17 04:54:48 PM
PostSubject